Publications
Publications
Show Results For
- All HBS Web
(632)
- Faculty Publications (243)
- Article
Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances
By: Josh Lerner, Hilary Shane and Alexander Tsai
- February 2003
- Article
Which Ties Matter When? The Contingent Effects of Interorganizational Partnerships on IPO Success
By: Ranjay Gulati and M. Higgins
This paper investigates the contingent value of interorganizational relationships at the time of a young firm's initial public offering (IPO). We compare the signaling value to young firms of having ties with two types of interorganizational partnerships: endorsement... View Details
- Article
Discontinuities and Senior Management: Assessing the Role of Recognition in Pharmaceutical Firm Response to Biotechnology
By: Rebecca M. Henderson, Sarah Kaplan and Fiona Murray
- November 2002 (Revised June 2003)
- Case
Monsanto: Leadership in a New Environment
By: Ray A. Goldberg, James Weber and James M Beagle
Monsanto is the biotechnology leader in agriculture. How does it use its leadership in Round Up to fund long-term research and development in biotechnology that is acceptable to the priority system of consumers in different parts of the world? Includes color exhibits. View Details
- April 2002
- Case
In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen
By: Juan Enriquez-Cabot, Gary P. Pisano and Gaye Bok
Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed... View Details
- April 2002
- Teaching Note
Anagene, Inc. TN
By: Robert S. Kaplan
Teaching Note for (9-102-030). View Details
- December 2001 (Revised June 2002)
- Case
Monsanto: Technology Cooperation and Small Holder Farmer Projects
By: James E. Austin, Diana Barrett and Stephanie Oestreich
As the leading plant technology company in the global food system, how can Monsanto share this technology with small-sale producers and not-for-profit researchers and institutions? View Details
- November 2001 (Revised December 2002)
- Case
Tracking Stocks at Genzyme (A)
Genzyme, a tracking stock pioneer, has used its innovative capital structure as a way to frame and grow its R&D-intensive business. Facing the question of how best to integrate a new acquisition into its tracking stock structure, Genzyme's top management is forced to... View Details
- October 2001
- Case
TIGR and ILRI: Solving Problems with Genomics
By: Ray A. Goldberg and James M Beagle
Discusses nonprofit institutional leadership applying advances in genetic science to solve health and animal problems in industrial countries and the developing world. View Details
- October 2001 (Revised April 2002)
- Case
Calgene, Inc.
By: Ray A. Goldberg and John T. Gourville
In 1993, Calgene is on the verge of introducing the world's first genetically engineered plant product--a tomato will taste better and stay fresh longer. At the same time, it is using biotechnology to produce improved plant products for the cottonseed and the... View Details
- October 2001 (Revised March 2002)
- Case
Perlegen Sciences
By: Linda A. Hill and Nicole Tempest
As a biotech start-up company involved in studying human genomes, Perlegen needed to develop an organization that fostered innovation and teamwork among a group of highly trained professionals from both the science and technology fields. Perlegen's CEO, Brad Margus,... View Details
- October 2001 (Revised March 2008)
- Case
Anagene, Inc.
By: Robert S. Kaplan and Christina L. Darwall
An entrepreneurial, publicly traded biotech company has begun production and sales of its core product--cartridges that permit DNA samples to be analyzed on a microchip. In the early quarters, sales are difficult to forecast and the company has experienced fluctuating... View Details
- September 2001
- Supplement
Millennium Pharmaceuticals, Inc. (B)
By: Stefan H. Thomke and Ashok Nimgade
Supplements the (A) case. View Details
- August 2001
- Case
Scios, Inc.
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details
- 2001
- Other Unpublished Work
Clusters of Innovation Initiative: San Diego
The study contains a conceptual framework for assessing the competitiveness of regional economies, an analysis of the San Diego region overall, as well as detailed assessments of two representative clusters—biotechnology/pharmaceuticals and communications. The report... View Details
- January 2001
- Case
Abgenix and the XenoMouse
By: Robert J. Dolan
Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to... View Details
- December 2000
- Case
Paradigm Genetics: The Industrialization of Genomics
By: Ray A. Goldberg, Carin-Isabel Knoop and Laure Mougeot Stroock
- October 2000
- Teaching Note
Kendle International Inc. TN
By: Dwight B. Crane and Indra Reinbergs
Teaching Note for (9-200-033). View Details